Biomarker Risk Model for Persistent MODS Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an urgent need to identify pediatric patients at risk of developing persistent multiple organ dysfunction syndrome (MODS) following cardiopulmonary bypass, as exaggerated inflammatory responses during cardiopulmonary bypass can lead to severe post-operative morbidity and mortality, and existing methods lack effective stratification for early prediction and management.
Innovation Solution
The method involves analyzing biomarker expression levels, specifically IL-8 and CCL3, at 4 and 12 hours post-CPB, along with patient age, to classify patients as high, intermediate, or low risk for persistent MODS, using a decision tree model that incorporates clinical data and additional biomarkers to guide clinical management and treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If biomarker analysis is performed to predict persistent MODS risk, then prediction accuracy is improved, but test complexity and cost increase
Solution Approach 1:
The patent extracts and measures only the most critical biomarkers (IL-8, CCL3, CCL4) at specific time points (4 and 12 hours post-CPB) rather than analyzing all possible inflammatory markers. This selective extraction of key predictive elements maintains high prediction accuracy while reducing test complexity and cost.
Solution Approach 2:
The patent segments the prediction process into distinct time points (4 hours and 12 hours post-CPB) and separates patients into risk categories (high, intermediate, low). This segmentation allows for staged biomarker analysis, where initial screening at 4 hours can guide whether more comprehensive 12-hour analysis is needed, balancing accuracy with resource utilization.
2Measurement precision
If multiple biomarkers are measured at multiple time points, then risk stratification accuracy is improved, but loss of time for treatment decision-making increases
Solution Approach 1:
The patent performs preliminary biomarker analysis at 4 hours post-CPB to identify patients with elevated inflammatory markers early. This preliminary action allows clinicians to initiate preventive interventions before persistent MODS develops, while the structured protocol ensures that additional 12-hour measurements are systematically integrated without causing treatment delays.
Solution Approach 2:
The patent implements a dynamic risk assessment protocol where the number and timing of biomarker measurements are adapted based on initial findings. Patients with concerning early markers undergo full 4-hour and 12-hour analysis, while low-risk patients may require fewer measurements, optimizing the balance between accuracy and time efficiency.
Data Source
AI summary
Methods and compositions disclosed herein generally relate to methods of identifying, validating, and measuring clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction, particularly as those responses relate to persistent multiple organ dysfunction syndrome (MODS) in pediatric patients following cardiopulmonary bypass (CPB). Certain aspects of the disclosure relates to identifying one or more biomarkers associated with septic shock in pediatric patients, obtaining one or more samples from a pediatric patient following CPB, then quantifying from the sample an amount of said biomarkers, wherein the level of said biomarker correlates with a predicted outcome.